Could fewer treatment procedures make wet AMD care easier to manage?
Roche has announced European Commission approval for Susvimo to treat neovascular age-related macular degeneration, commonly known as wet AMD. The treatment delivers medicine continuously through a refillable eye implant, with scheduled refills every 6 months.
How does Susvimo work?
Susvimo is a formulation of ranibizumab used with Contivue, a device surgically implanted in the eye during an outpatient procedure. The implant releases medicine over time and is refilled, offering an alternative to frequent injections.
This distinction matters: twice-yearly refills do not mean patients only need care twice a year. Implantation and ongoing monitoring remain part of the pathway.
What did the clinical trial show?
In the Phase III Archway study, Susvimo maintained vision outcomes equivalent to monthly ranibizumab injections. Roche also reported that approximately 95% of patients receiving twice-yearly refills needed no additional anti-VEGF treatment in its cited long-term data.
What could this mean for patients?
The potential benefit is easy to understand: fewer treatment procedures could mean less disruption to everyday life.
For someone coordinating care with a partner, family member or friend, a more manageable treatment schedule could make a meaningful difference. That is a useful way to frame innovation: alongside clinical outcomes, ask what the experience of receiving care actually looks like.
Clear conversations will be essential. Patients need to understand the procedure, its risks, the follow-up involved and whether the approach suits their individual circumstances.
What should ophthalmology teams consider?
From a service-planning perspective, we see several questions worth asking before introducing a different treatment pathway:
- Who would assess patients and explain their options?
- What surgical capacity and staff training would be needed?
- How would refills and follow-up fit into existing clinic schedules?
- Who would coordinate care across the team?
These are implementation considerations, rather than evidence that the treatment will automatically free up capacity. Services would need to assess the full pathway, including the work required to establish it.
Stay connected with Vision Executives.
Follow Vision Executives on LinkedIn to stay up to date with the latest eye care industry news, insights and job vacancies across ophthalmology, optometry, optical retail and medical technology.